101 related articles for article (PubMed ID: 15781479)
21. Osteopontin in urinary stone formation.
Hoyer JR; Otvos L; Urge L
Ann N Y Acad Sci; 1995 Apr; 760():257-65. PubMed ID: 7785900
[No Abstract] [Full Text] [Related]
22. Protein regulation of intrarenal crystallization.
Kumar V; Lieske JC
Curr Opin Nephrol Hypertens; 2006 Jul; 15(4):374-80. PubMed ID: 16775451
[TBL] [Abstract][Full Text] [Related]
23. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test.
Voss S; Hesse A; Zimmermann DJ; Sauerbruch T; von Unruh GE
J Urol; 2006 May; 175(5):1711-5. PubMed ID: 16600737
[TBL] [Abstract][Full Text] [Related]
24. Role of cellular oxalate in oxalate clearance of patients with calcium oxalate monohydrate stone formation and normal controls.
Oehlschläger S; Fuessel S; Meye A; Herrmann J; Froehner M; Albrecht S; Wirth MP
Urology; 2009 Mar; 73(3):480-3. PubMed ID: 19167040
[TBL] [Abstract][Full Text] [Related]
25. Prevention of stone disease.
Porena M; Guiggi P; Micheli C
Urol Int; 2007; 79 Suppl 1():37-46. PubMed ID: 17726351
[TBL] [Abstract][Full Text] [Related]
26. Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis.
Gohel MD; Shum DK; Tam PC
Carbohydr Res; 2007 Jan; 342(1):79-86. PubMed ID: 17145044
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
[TBL] [Abstract][Full Text] [Related]
28. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
29. A simple procedure for isolating microgram quantities of biologically active bikunin from human urine.
Yang L; Resnick MI; Marengo SR
BJU Int; 2005 Sep; 96(4):647-53. PubMed ID: 16104926
[TBL] [Abstract][Full Text] [Related]
30. Urinary macromolecules and renal tubular cell protection from oxalate injury: comparison of normal subjects and recurrent stone formers.
Tsujihata M; Tsujikawa K; Tei N; Yoshimura K; Okuyama A
Int J Urol; 2006 Mar; 13(3):197-201. PubMed ID: 16643608
[TBL] [Abstract][Full Text] [Related]
31. Post-translational modification and proteolytic processing of urinary osteopontin.
Christensen B; Petersen TE; Sørensen ES
Biochem J; 2008 Apr; 411(1):53-61. PubMed ID: 18072945
[TBL] [Abstract][Full Text] [Related]
32. Mechanism underlying the low prevalence of pediatric calcium oxalate urolithiasis.
Momohara C; Tsujihata M; Yoshioka I; Tsujimura A; Nonomura N; Okuyama A
J Urol; 2009 Sep; 182(3):1201-9. PubMed ID: 19625038
[TBL] [Abstract][Full Text] [Related]
33. [Glycoproteins, glycosaminoglycans, and urolithiasis].
Grases F; Costa-Bauzá A; Llobera A
Med Clin (Barc); 1995 Jun; 105(1):31-5. PubMed ID: 7637413
[No Abstract] [Full Text] [Related]
34. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
[TBL] [Abstract][Full Text] [Related]
35. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status.
Thamilselvan S; Menon M
BJU Int; 2005 Jul; 96(1):117-26. PubMed ID: 15963133
[TBL] [Abstract][Full Text] [Related]
36. Effect of high and low calcium diets on stone forming risk during liberal oxalate intake.
Matsumoto ED; Heller HJ; Adams-Huet B; Brinkley LJ; Pak CY; Pearle MS
J Urol; 2006 Jul; 176(1):132-6. PubMed ID: 16753387
[TBL] [Abstract][Full Text] [Related]
37. Epitaxial deposition of calcium oxalate on uric acid rich stone matrix is induced by a 29 kDa protein.
Srinivasan S; Kalaiselvi P; Varalakshmi P
Clin Chim Acta; 2006 Feb; 364(1-2):267-74. PubMed ID: 16139257
[TBL] [Abstract][Full Text] [Related]
38. A gel model for measuring crystallization inhibitor activities.
Schneider HJ; Bothor W; Berg W; Börner RH; Jakob M
Urol Int; 1983; 38(1):33-8. PubMed ID: 6836779
[No Abstract] [Full Text] [Related]
39. Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development.
Costa-Bauzá A; Isern B; Perelló J; Sanchis P; Grases F
Scand J Urol Nephrol; 2005; 39(3):194-9. PubMed ID: 16118089
[TBL] [Abstract][Full Text] [Related]
40. Could high plasma bikunin predict a favorable outcome in ovarian cancer?
McIntosh M
Nat Clin Pract Oncol; 2005 Oct; 2(10):502-3. PubMed ID: 16205769
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
